CI
ACAD icon

Cowen Inc’s Acadia Pharmaceuticals ACAD Stock Holding History

Cowen Inc’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-13,600
Closed -$208 – 501
2018
Q2 		$208 Buy
+13,600
New +$242K 0.01% 323
2015
Q2 		– Sell
-40,000
Closed -$1.3M – 465
2015
Q1 		$1.3M Buy
+40,000
New +$1.37M 0.11% 114

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen Inc's ACAD Position: Q3 2018 in Review

Cowen Inc sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 7,500 shares — an estimated $115 sold.

Cowen Inc first reported a position in ACAD in Q1 2015 and held it in 5 quarters. The position peaked at $1.35M in Q1 2015. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

  • Cowen Inc reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cowen Inc sold 7,500 Acadia Pharmaceuticals shares in Q3 2018, an estimated $115.
  • Cowen Inc first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 5 quarters.
  • Cowen Inc's Acadia Pharmaceuticals position peaked at $1.35M in Q1 2015.
  • 184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Cowen Inc's 13F filing for Q3 2018, filed 13 Nov 2018.